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Purpose. To evaluate the results and quality of life of patients with resistant of castration-resistant tumors previously treated with
Insulin-potentiation therapy (IPT) combined with hormone therapy. Materials and methods. Sixteen patients with metastasis
prostate tumors after bilateral castration, androgenic blockade, and progression of the disease were observed during the study.
The patients were divided into two groups: group A consisting of 8 patients treated with low-dose chemotherapy Epirubicin,
Vinblastine, and Cyclophosphamide combined with LHRH agonist and group B consisting of another 8 patients treated with low-
dose chemotherapy Docetaxel combined with LHRH agonist. Results. The overall (groups A and B) results concerning PSA after
the sixth IPT show partial eﬀect in 8 out of 16 (50%) patients, stabilization in 4 out of 16 (25%), and progression in 4 out of
16 (25%). The median survival for all treated patients is 11,7 months (range 3–30 months). During the treatment no signiﬁcant
side eﬀects were observed, and no lethal cases occurred. Conclusion. In spite of the small number of the treated patients with
castration-resistant prostate tumors, the preliminary results are promising and this gives us hope and expectations for future
serious multicenter research over the possibilities for routine implementation of IPTLD.
1.Introduction
In spite of the eﬃcacy of standard androgen deprivation
therapy for metastasis tumors of prostate gland, almost all of
the patients progress with their disease. In the last few years
the prostate tumors progress although the androgen block-
ade is deﬁned as castration-resistant prostate cancer—CRPC
[1, 2].
Despite obvious eﬀorts for revealing the reasons for hor-
monal resistance after androgen deprivation, the treatment
remains a challenge.
The duration of remission after treatment of hormone-
resistant tumors of prostate gland with secondary hormonal
manipulation is short and there is no serious impact on
survival [3].
Up to 1990 the results after chemotherapy for hormone-
resistant tumors of prostate gland are disappointing. Later a
Canadian researcher drew our attention to the potentialities
of the combination Mitoxantrone with Prednisone where an
improvement in pain and quality of life was indicated but
there was no eﬀect on the survival [3, 4].
In 2004 two trials registered and prolonged survival after
using Docetaxel. The overall survival with Docetaxel was
18,9 months against 16,5 months with Mitoxantrone and
Prednisolone. There were registered improvements also in
toxicity and quality of life. At this moment the treatment
with Docetaxel in combination with Prednisone is accepted
asstandardofcareformetastaticcastration-resistantprostate
tumors [5, 6].
In a process of investigation there are some new chemo-
therapeutic agents like Epothilones and Satraplatin [7, 8].
In standard chemotherapy used for treatment of diverse
tumors, we usually use the maximum tolerated dose (MDT)
as we intend to achieve better results. Despite many clinical2 ISRN Urology
researches with diﬀerent combinations of chemotherapeu-
tics, the progress in eﬀectiveness is very modest and there are
many toxic eﬀects.
On the other hand prolonged intervals between the
applications of the chemotherapeutics are factors which con-
tribute to chemoresistance.
In searching other possibilities for reducing the toxic
eﬀects of chemotherapy without decreasing its antitumor
eﬃcacy in the last few years intensive researches have been
made on chemotherapy in low doses and in short inter-
vals between the applications—the so-called metronom-
ic chemotherapy. Preclinical research and small clinical re-
search show serious possibilities for lowering the toxic eﬀects
without diminishing the eﬃcacy [9, 10].
Usageoflowdoseschemotherapeuticswithincreasedfre-
quency suggests another method called insulin-potentiated
therapy (IPT) or now called insulin-potentiated targeted
low-dose therapy (IPTLD), where standard schemes of
chemotherapy are used in combination with intravenous
insulin, 10 times lower doses of chemotherapeutics, and
short intervals between the applications. This treatment has
verylowtoxicityandourpersonalexperienceshowsthateﬃ-
ciencyisnotdeferringfromthestandardchemotherapy[11].
According to our previous experience in implementation
of IPTLD in diﬀerent tumors including castration resistant
prostate, tumors we conducted a research for new possibili-
ties where our main target was to improve the quality of life
[12, 13].
This study is focusing on the potential of IPTLD in
combinationwithhormonetherapyfortreatmentofpatients
with castration-resistant prostate tumors.
2. Patientsand Method
Between April 2006 and May 2011 a total of 406 patients
with diverse tumors were treated with IPTLD and 21 out
of them were with prostate cancer. Sixteen of them were
with advanced prostate cancer (Stage III-Stage IV and
nodal, bone, or visceral secondary) and cynically apparent
hormonal independence entered the study.
They were divided into two groups: group A: 8 patients
treated with Epirubicin, Vinblastine, and Cyclophosphamide
in combination with LHRH agonist (Goserelin depot
3,6mg). In group B another 8 patients were treated with
Docetaxel in combination with LHRH agonist (Goserelin
depot 3,6mg).
Before the treatment all patients gave informed content.
The main requirement for eligibility was objective and
subjective data for progression of the disease after surgical
castration, androgenic therapy, and androgen withdrawal.
In Table 1 the clinical characteristics of treated patients are
presented.
Pretreatment evaluation of the patients includes history
of the disease, physical exam, Karnofsky performance status
(KPS),subjectiveconditionevaluatedwithBeretta[14],FBC,
biochemistry including AF, prostate-speciﬁc antigen (PSA),
urine analysis, chest radiographs, ultrasound, bone scan, and
CT.
Table 1: Clinical characteristics of the treated patients.
Clinical parameters Group A Group B
Total number of patients 8 8
Age
Median 64 66
Range 56–76 53–73
Karnovsky performance scale (mean)
Median 68 74
Range 50–80 60–90
Beretta score before treatment
Median 24 24
Range 10–42 6–33
Glison score
41 0
51 1
60 1
72 1
81 0
93 3
Unknown 0 2
Tumor stage
Stage III 0 0
Stage IV 8 8
Extend of disease (nr.)
With local metastases 3 (8) 3 (8)
With distant metastases 7 (8) 7 ( 8)
Previous therapy
Surgical orchiectomy 6 (8) 5 (8)
Antiandrogens 8 (8) 7 (8)
Palliative radiotherapy 4 (8) 0
PSA(ng/mL)
Median 389,6 1511,2
Range 63,3–1320 17,16–8395
Al. phosphatase mg/mL
Median 1673 1120
Range 246–4286 253–5264
Control lab exams include tumor markers after 6th IPT
application and after every fourth IPT after that and control
exams of bone scan and CT—after the 10th application and
after that on 3- or 6-month intervals from the beginning.
Every month patients complete Berettas questionnaire for
their subjective state and we note only sections A and B in
Table 4.
3. Treatment
3.1. Insulin Potentiation Therapy (IPT).
(1) GroupA:insulini.v.(0,4UI/kg.)incombinationwith
Cyclophosphamide (0,10–0,15g/m2)/Epirubicin
(3mg/m2); Vinblastine (0,5mg/m2) i.v. in 8 patients.
(2) GroupB:insulini.v.(0,4UI/kg.)incombinationwith
Docetaxel (3,6mg/m2) i.v. in 8 patients.ISRN Urology 3
Length of one scan treatment: 6 applications in every 5-
day interval, then sustaining treatment in gradual increasing
intervals(fourapplicationsin10days,2,3,andmoreweeks).
In the interval, have Dexamethason, 20mg; Cyclophos-
phamide, 50mg p.o.; Doxycyclin, 100mg; Legalon, 3 ×
140mg; Celebrex, 2 × 7,5mg; antioxidants, and ozone ther-
apy.
Maintaining treatment consists of no more than 24 IPT
applications.
Hormone Therapy. Six application (one per month) with
LHRH agonist (Goserelin depot 3, 6mg) in every 28 days for
six months.
Objective Response. to treatment was assessed as per PSA
levels and bone scan results. A complete response required
normal PSA levels and normal bone scan. A partial response
required a decrease of >50% of the baseline value of PSA and
decrease in the measurable lesions seen on the bone scan and
also the absence of signs of disease progression. Stabilization
of disease was deﬁned as decrease of <50% of the baseline
levels of PSA, an absence of increase of lesions seen on the
bone scan. Patients were considered to have disease progres-
sion if they showed an increase in 2 successive PSA level
measurements and/or appearance of new neoplastic lesions.
Additional Parameters. For evaluation the eﬀect of the treat-
ment includes mean remission duration and median overall
survival.
Quality of Life. It was reported every month with Beretta
Questionnaire.
The Toxicity. The toxicity of treatment is recorded according
to the criteria of World Health Organization (WHO).
4. Results
The mean follow-up period was 7,6 months (2 to 23
months). Sixteen patients ﬁnished the core cycle of 6 appli-
cations. After 6th IPT application 3 patients of group A and
4 patients of group B discontinued the treatment because of
social reasons. In group A we implemented 159 IPT applica-
tions and in group B 106.
Treatment is very well tolerated by the patients. During
the treatment no signiﬁcant side eﬀects were observed, and
no lethal cases occurred. Common side eﬀects include light
weakness and sleepiness on the day of the procedure.
Two (16) patients complained of nausea and vomiting
a few hours after the procedure but this disappears on the
next day. Slight reduce in hemoglobin is observed in 6 of 16
patients.Bloodtransfusionwasnecessarybeforetreatmentin
3 and during it in 2 patients with low starting hemoglobin.
Slight increase in liver enzymes is observed in 5 from 16.
These lab changes did not inﬂuence the subjective status of
thepatients.Slightincreaseincreatinineandureaisobserved
in one patient after previous nephrectomy. Changes in lab
results are in parameters of grade 0 of WHO criteria.
Table 2: Treatment results (after 6 IPT).
Group A Group B Overall
nn n (%)
Complete response 0 0 0
Partial response 5 (8) 3 (8) 8/16 (50)
Stabile disease 2 (8) 2 (8) 4/16 (25)
Progressive disease 1 (8) 3 (8) 4/16 (25)
Table 3: Treatment results (after 10 IPT).
Group A Group B Overall
nn n (%)
Complete response 1 (5) 2 (4) 3/9 (33)
Partial response 0 (5) 1 (4) 1/9 (11)
Stabile disease 2 (5) 0 (4) 2/9 (22)
Progressive disease 2 (5) 1 (4) 3/9 (33)
Theresultsafter6thIPTconcerningPSAcriteriaforboth
groups show partial eﬀect in 8 of 16p. (50%), stabilization
in 4 out of 16 (25%), and progression in 4 out of 16
(25%). Usually the improvement occurs after the ﬁrst 2
IPT applications. The results after 10th IPT show complete
response in 3 of 9 (33%), partial response in 1 of 9 (11%),
stabilization in 2 of 9 (22%) and progression in 3 of 9 (33%).
In Table 2 are presented the results of treatment accord-
ing to PSA criteria after the end of the core 6 weekly course
of IPT. In Table 3 are presented the results after 10th IPT or 3
months after the beginning.
The mean values of PSA in those who responded to the
treatment decrease from 256,7 to 94,6ng/mL in group A
and from 2215,3ng/mL to 956,2ng/mL in group B after 6th
(course of treatment) IPT. After the 10th course of treatment
the values were, respectively, 36,3nag/mL in group A and
4,9nag/mL in group B.
The mean duration of the remission in group A is 7,6
months (range 3–18 months) and for group B it is10 months
(range 3–18 months). The median survival for all treated
patients is 11,7 months (range 3–30 months).
Subjective improvement is observed in all patients in
bothgroups,averagefrom24,2pointsbeforetreatmentto8,9
points after 6th IPTLD. More than 50% decrease in sympto-
matic index is observed in 7 (8) from group A and 3 (8) from
group B.
In Figures 1 and 2 are presented the results from the sub-
jective improvement in both groups after 6th IPT.
5. Discussion
The method of insulin potentiation therapy was empirically
invented in 1930 from Mexican doctor D. Perez Garsia, who
was applying it successfully for the treatment of chronic
and oncology diseases for 41 years. Lately his practice is
continued by his son and grandson who now gathers more
andmorepopularityandthemethodisusedinpracticefrom
increasing number of doctors (more then 400) and clinics all
around the world.4 ISRN Urology
Table 4: Beretta Self-Compilation Questionnaire.
Self-Compilation Questionnaire for weekly determination of subjective status
The patient should cross the circle corresponding to the worst feeling in the week
Subjective factors
Coding deﬁnition
01 2 3 4
No Little Enough Much Very Much
Section A
(1) Feeling ill         
(2) Feeling bad         
(3) Feeling anxious         
(4) Feeling depressed         
(5) Presence of nausea         
(6) Losing appetite         
(7) Reduced working capacity (usual job)         
(8) Reduced housework and concentration capacity         
(9) Reduced social activities         
(10) Reduced sexual activity         
Section B
(11) Presence of fatigue         
(12) Presence of respiratory distress         
(13) Presence of pain         
Section C
(14) Is treatment helping?         
(15) Is doctor helping?         
(16) Is nursing staﬀ helping?         
(17) Is hospital centre helping?         
(18) Is family helping?         
(19) Is social “milieu” helping?         
(20) Is any other person/service/institution helping?         
See [15].
The theoretical conception for the mechanisms of action
of IPT is explained in two publications of Ayre S. G., D.
Perez Garcia y Bellon, and D. Perez Garcia, in 1986 and
2000 [10, 16]. Same authors in 1990 submitted in European
JournalofCanceronecasefromtheirpracticedemonstrating
complete tumor regression of ductal breast carcinoma in 32-
year woman explaining the mechanisms and method that
they had use [17].
In 2003 Lasalvia-Prisco et al. published in Cancer
Chemotherapy and Pharmacology the ﬁrst clinical research
investigating the eﬀect of the combination of insulin and
Methotrexate in patients with breast cancer [18].
Basic role for the eﬃcacy of the method plays the usage
of hormone insulin in diabetics. Despite of the diversity of
the actions of the insulin in the human body not all of them
areunrevealed.In1960smanyinvestigationswereconducted
and they show that besides its eﬀect in lowering the blood
sugar insulin has serious eﬀect in the whole metabolism:
(i) increases the permeability of cell membrane,
(ii) inﬂuences the metabolic processes in human body
with the increase of the regenerating processes,
(iii) facilitates the transport of intra and extra cellular
liquids which helps the organism to eliminate the
toxic products,
(iv) have other endocrine eﬀects: directly stimulates
suprarenal gland to produce epinephrine and gluco-
corticoid hormones and stimulates ACTH secretion.
These endocrine eﬀects also have a positive inﬂuence
on the regenerating processes.
Various researches show that insulin hormone has a
signiﬁcant impact also on the tumor cells themselves. As a
result of the current knowledge of the eﬀect of insulin on
biology of tumor cells several conclusions can be done.
(i) Increased permeability after the insulin eﬀect on the
cellular membrane results in increased intracellular
quantity of antitumor agents.
(ii) Insulin inﬂuences the intracellular metabolism of the
tumor cell, which leads to increase of the number of
cells in phase S, where they are with highly sensitive
to speciﬁc chemotherapeutics.ISRN Urology 5
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Figure 1: Quality of life assessment according to Berreta Symptoms
Index, after the 6th IPT course for group A.
(iii) The increased number of insulin receptors on the
tumor cell, in comparison to the normal one, allows
the before mentioned 2 factors to act predominantly.
Despite the serious achievements in the ﬁeld of revealing
the intimate mechanisms of the action of the insulin hor-
mone in the human body we are still far away from getting
answers to all our questions. Future researches will probably
reveal more details regarding the eﬀective clinical usage of
insulin.
Having in mind the serious problems of the treatment
of hormone-resistant prostate tumors and taking into con-
sideration previous experimental researches, we conducted
a clinical research on the direct inhibitory eﬀect of LHRH
analog Triptorelin acetate depot on the cellular proliferation.
The results conﬁrmedlocal inhibitory actionfromthe exper-
imental researches and showed that they can successfully be
combined with chemotherapy [19, 20].
In search of a new method for lowering the toxicity
of the chemotherapy for treating oncological diseases, we
began in 2006 to implement IPTLD combined with LHRH
agonistGosrelindepot3,6mg.Amongthealltreatedpatients
21 are with advanced prostate tumors, 16 are hormone-
resistant, and those 16 are divided according to the used
chemotherapeutics into 2 groups—group A and group B.
Afterthe ﬁrst6IPTapplications overall(groups A andB)
responsetotreatmentonPSAcriteriashowspartialeﬀectand
stabilizationin12of16(75%)patients.Afterthe10thIPTLD
application or 3 months after starting treatment, complete
response, partial response, and stabilization were observed
in 4 of 9 (66.6%), while in 3 of 9 (33.3%) was registered
complete eﬀect.
Symptomatic improvement of the treatment after the
sixth IPTLD is observed in all patients in both groups. More
than 50% improvement in symptomatic index was reported
in 10 of 16 (62.5%) for the same period.
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Figure 2: Quality of life assessment according to Berreta Symptoms
Index, after the 6th IPT course for group B.
The mean duration of remission in patients with com-
plete response in both groups was 17 (range 15–18 months)
months. In one patient treated with Docetaxel, after a 15-
month remission that progressed we used again IPTLD with
Cyclophosphamide, Epirubicin, and Vinblastin in combina-
tionwithILHRHagonist.AfterthesixthapplicationthePSA
values decreased from 399,9ng/mL to 35,0ng/mL.
Despite the advanced stage of disease in patients treated
by us, the treatment is well tolerated without any serious side
eﬀects. Quality of life after the second IPTLD application is
signiﬁcantly improved, and this applies even to patients with
treatment failure in terms of PSA criteria.
The reasons for discontinuation of the treatment are
mainly social and primarily ﬁnancial. The research was
carried out in a private medical centre and the ﬁnancial
expenses are not covered by the National Health Insurance
Institution. This reﬂects the limited opportunities for long-
term monitoring of health outcomes. Still the small number
oftreatedpatientsandtheshort-termofthefollow-updonot
allow us to do a serious comparative analysis of the results of
the treatment in both groups, as well as making deﬁnitive
conclusions regarding the eﬀectiveness of the treatment. The
preliminary presented results give us reason to assume that
extensive comparative researches are necessary for better
proving the eﬀectiveness of the method.
6. Conclusion
Our present experience with IPTLD (in more than 400
treated patients) with various tumors as well as the practical
experience of the growing number of doctors practicing the
method gives us a reason to assume that IPTLD method
provides a real opportunity for resolving one of the most
serious problems of toxicity associated with chemotherapy
using maximum tolerated doses. A certain advantage of
the method along with its eﬀectiveness is the signiﬁcantly
improved quality of life of the treated patients.6 ISRN Urology
Inspiteofthesmallnumberofpatientstreatedbyuswith
castrate-resistant prostate tumor, the preliminary results are
promising and this gives us hope and expectations for future
serious researches on the potential of widespread clinical use
of IPTLD.
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